Aktuelle Urol 2021; 52(05): 445-451
DOI: 10.1055/a-1364-4633
Originalarbeit

Perkutane lokal-ablative Therapie beim kleinen Nierenzellkarzinom

Percutaneous local ablation of small renal cell cancer
Medizinische Hochschule Hannover, Institut für Diagnostische und Interventionelle Radiologie, Hannover
› Author Affiliations

Zusammenfassung

Das Nierenzellkarzinom (NCC) ist eine Tumorerkrankung v. a. älterer Menschen. Perkutane lokale Therapien kleiner NCC (< 4 cm) nehmen insbesondere vor dem Hintergrund begleitender Komorbiditäten und eingeschränkter OP-Fähigkeit der Patienten zu. In dem vorliegenden Beitrag werden etablierte lokale ablative Verfahren in Form der Radiofrequenz- (RFA), Mikrowellen- (MWA) und Kryoablation dargestellt, und der Stellenwert der Ablation in der Behandlung kleiner NCC basierend auf aktueller Evidenz und im Kontext von bestehenden Leitlinien erläutert.

Abstract

Renal cell carcinoma (RCC) is a cancer that mainly occurs in elderly patients. Percutaneous image-guided ablation of small RCC (< 4 cm) is a validated therapeutic option, especially as many patients are no candidates for surgery due to comorbidities. This article presents and discusses established local ablative techniques such as radiofrequency (RFA), microwave (MWA) and cryoablation for the treatment of small RCC based on current literature and in the context of the latest guidelines.



Publication History

Article published online:
15 April 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • Literaturverzeichnis

  • 1 Robert Koch Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland. Krebs in Deutschland 2007/2008. 2012 Im Internet (Stand 16.01.2021): www.rki.de/krebs
  • 2 Escudier B, Porta C, Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 706-720
  • 3 Volpe A, Panzarella T, Rendon RA. et al. The Natural History of Incidentally Detected Small Renal Masses. Cancer 2004; 100: 738-745
  • 4 Morris CS, Baerlocher MO, Dariushnia SR. et al. Society of Interventional Radiology Position Statement on the Role of Percutaneous Ablation in Renal Cell Carcinoma. J Vasc Interv Radiol 2020; 31: 189-194
  • 5 Ahmed M. Image-guided tumor ablation: Standardization of terminologyand reporting criteria - A 10-Year update: Supplement to the consensus document. J Vasc Interv Radiol 2014; 25: 1706-1708
  • 6 Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: A unified approach to underlying principles, techniques, and diagnostic imaging guidance. Am J Roentgenol 2000; 174: 323-331
  • 7 Hong K, Georgiades CS. Radiofrequency Ablation: Mechanism of action and devices. In: Hong K, Georgiades CS. Percutaneous Tumor Ablation. New York: Thieme; 2011: 1-14
  • 8 Krokidis ME, Orsi F, Katsanos K. et al. CIRSE Guidelines on Percutaneous Ablation of Small Renal Cell Carcinoma. Cardiovasc Intervent Radiol 2017; 40: 177-191
  • 9 Ringe KI, Panzica M, von Falck C. Thermoablation of Bone Tumors. RoFo 2016; 188: 539-550
  • 10 Wolf F, Dupuy D. Microwave Ablation: Mechsnism of action and devices. In: Hong K, Georgiades CS. Percutaneous Tumor Ablation. New York: Thieme; 2011: 27-44
  • 11 Brace CL, Laeseke PF, Sampson LA. et al. Microwave ablation with multiple simultaneously powered small-gauge triaxial antennas: Results from an in vivo swine liver model. Radiology 2007; 244: 151-156
  • 12 Skonieczki BD, Wells C, Wasser EJ. et al. Radiofrequency and microwave tumor ablation in patients with implanted cardiac devices: Is it safe?. Eur J Radiol 2011; 79: 343-346
  • 13 Georgiades CS, Marx JK. Cryoablation: Meachnism of action and devices. In: Hong K, Georgiades CS. Percutaneous Tumor Ablation. New York: Thieme; 2011: 15-26
  • 14 Callstrom MR, Kurup AN. Percutaneous ablation for bone and soft tissue metastases-why cryoablation?. Skeletal Radiol 2009; 38: 835-839
  • 15 Veltri A, De Fazio G, Malfitana V. et al. Percutaneous US-guided RF thermal ablation for malignant renal tumors: Preliminary results in 13 patients. Eur Radiol 2004; 14: 2303-2310
  • 16 Patel IJ, Rahim S, Davidson JC. et al. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part II: Recommendations. J Vasc Interv Radiol 2019; 30: 1168-1184
  • 17 Wah TM, Irving HC. Infectious Complications after Percutaneous Radiofrequency Ablation of Renal Cell Carcinoma in Patients with Ileal Conduit. J Vasc Interv Radiol 2008; 19: 1382-1385
  • 18 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 2.0. 2020 Im Internet (Stand 16.01.2021): www.leitlinienprogramm-onkologie.de/leitlinien/nierenzellkarzinom/
  • 19 Wah TM, Koenig P, Irving HC. et al. Radiofrequency ablation of a central renal tumor: Protection of the collecting system with a retrograde cold dextrose pyeloperfusion technique. J Vasc Interv Radiol 2005; 16: 1551-1555
  • 20 Tacke J, Mahnken A, Bücke A. et al. Nephron-sparing percutaneous ablation of a 5 cm renal cell carcinoma by superselective embolization and percutaneous RF-ablation. RoFo 2001; 173: 980-983
  • 21 Katsanos K, Mailli L, Krokidis M. et al. Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours. Cardiovasc Intervent Radiol 2014; 37: 427-437
  • 22 El Dib R, Touma NJ, Kapoor A. Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. BJU Int 2021; 110: 510-516
  • 23 Gervais DA, McGovern FJ, Arellano RS. et al. Radiofrequency ablation of renal cell carcinoma: Part I, indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol 2005; 185: 64-71
  • 24 Katsanos K, Mailli L, Krokidis M. et al. Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours. Cardiovasc Intervent Radiol 2014; 37: 427-437
  • 25 Georgiades CS, Rodriguez R. Efficacy and Safety of Percutaneous Cryoablation for Stage 1A/B Renal Cell Carcinoma: Results of a Prospective, Single-Arm, 5-Year Study. Cardiovasc Intervent Radiol 2014; 37: 1494-1499
  • 26 Guo J, Arellano RS. Percutaneous Microwave Ablation of Category T1a Renal Cell Carcinoma: Intermediate Results on Safety, Technical Feasibility, and Clinical Outcomes of 119 Tumors. AJR Am J Roentgenol 2021; 216: 117-124
  • 27 John JB, Anderson M, Dutton T. et al. Percutaneous microwave ablation of renal masses in a UK cohort. BJU Int 2020; DOI: 10.1111/bju.15224.
  • 28 Zhou M, Mills A, Noda C. et al. SEER study of ablation versus partial nephrectomy in cT1A renal cell carcinoma. Futur Oncol 2018; 14: 1711-1719
  • 29 Xing M, Kokabi N, Zhang D. et al. Comparative effectiveness of thermal ablation, surgical resection, and active surveillance for T1a renal cell carcinoma: A surveillance, epidemiology, and end results (SEER)–Medicare-linked population study. Radiology 2018; 288: 81-90
  • 30 Shi L, He Y, Liu C. et al. Local ablation vs partial nephrectomy in T1N0M0 renal cell carcinoma: An inverse probability of treatment weighting analysis. Cancer Med 2020; 9: 7988-8003
  • 31 Kokabi N, Xing M, Duszak R. et al. Sociodemographic disparities in treatment and survival of small localized renal cell carcinoma: Surgical resection versus thermal ablation. J Comp Eff Res 2016; 5: 441-452
  • 32 Cazzato RL, Garnon J, De Marini P. et al. Is percutaneous image-guided renal tumour ablation ready for prime time?. Br J Radiol 2020; 93: 20200284 DOI: 10.1259/bjr.20200284.
  • 33 Ljungberg B, Albiges L, Abu-Ghanem Y. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol 2019; 75: 799-810
  • 34 Campbell S, Uzzo RG, Allaf ME. et al. Renal Mass and Localized Renal Cancer: AUA Guideline. J Urol 2017; 198: 520-529
  • 35 Finelli A, Ismaila N, Bro B. et al. Management of small renal masses: American society of clinical oncology clinical practice guideline. J Clin Oncol 2017; 35: 668-680
  • 36 Motzer RJ, Jonasch E, Dror Michaelson M. et al. Featured updates to the NCCN guidelines. JNCCN J Natl Compr Cancer Netw 2019; 17: 1278-1285